{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:20:13Z","timestamp":1760955613584},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.phrs.2015.10.018","type":"journal-article","created":{"date-parts":[[2015,11,4]],"date-time":"2015-11-04T23:10:27Z","timestamp":1446678627000},"page":"49-55","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["The use of ranolazine in non-anginal cardiovascular disorders: A review of current data and ongoing randomized clinical trials"],"prefix":"10.1016","volume":"103","author":[{"given":"Christos G.","family":"Mihos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rama K.","family":"Krishna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nisharahmed","family":"Kherada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maiteder","family":"Larrauri-Reyes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Tolentino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orlando","family":"Santana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2015.10.018_bib0005","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/cvr\/cvt145","article-title":"The arrhythmogenic consequences of increasing late INa in the cardiomyocyte","volume":"99","author":"Shryock","year":"2013","journal-title":"Cardiovasc. Res."},{"issue":"Suppl. 4","key":"10.1016\/j.phrs.2015.10.018_bib0010","first-page":"iv6","article-title":"Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine","volume":"92","author":"Belardinelli","year":"2006","journal-title":"Heart"},{"key":"10.1016\/j.phrs.2015.10.018_bib0015","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1161\/01.CIR.0000139333.83620.5D","article-title":"Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties","volume":"110","author":"Antzelevitch","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2015.10.018_bib0020","first-page":"185","article-title":"Cardiac ion channels","volume":"2","author":"Grant","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2015.10.018_bib0025","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.cardiores.2005.08.015","article-title":"A multi-modal composition of the late Na+ current in human ventricular cardiomyocytes","volume":"69","author":"Maltsev","year":"2006","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.phrs.2015.10.018_bib0030","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/978-3-642-41588-3_7","article-title":"The role of late I Na in development of cardiac arrhythmias","volume":"221","author":"Antzelevitch","year":"2014","journal-title":"Handb Exp. Pharmacol."},{"issue":"Suppl. 4","key":"10.1016\/j.phrs.2015.10.018_bib0035","first-page":"iv1","article-title":"Late sodium current in the pathophysiology of cardiovascular disease: consequences of sodium-calcium overload","volume":"92","author":"Noble","year":"2006","journal-title":"Heart"},{"key":"10.1016\/j.phrs.2015.10.018_bib0040","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10557-012-6430-0","article-title":"The late Na+ current\u2013origin and pathophysiological relevance","volume":"27","author":"Zaza","year":"2013","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.phrs.2015.10.018_bib0045","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10557-012-6421-1","article-title":"Role of late sodium channel current block in the management of atrial fibrillation","volume":"27","author":"Burashnikov","year":"2013","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.phrs.2015.10.018_bib0050","first-page":"260","article-title":"The use of oral ranolazine to convert new or paroxysmal atrial fibrillation: a review of experience with implications for possible pill in the pocket approach to atrial fibrillation","volume":"9","author":"Murdock","year":"2009","journal-title":"Indian Pacing Electrophysiol. J."},{"key":"10.1016\/j.phrs.2015.10.018_bib0055","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/europace\/eut407","article-title":"Ranolazine enhances the efficacy of amiodarone for conversion of recent-onset atrial fibrillation","volume":"16","author":"Koskinas","year":"2014","journal-title":"Europace"},{"key":"10.1016\/j.phrs.2015.10.018_bib0060","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.amjcard.2012.04.044","article-title":"Comparison of effectiveness of ranolazine plus amiodarone versus amiodarone alone for conversion of recent-onset atrial fibrillation","volume":"110","author":"Fragakis","year":"2012","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.phrs.2015.10.018_bib0065","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1161\/CIRCULATIONAHA.107.724880","volume":"116","author":"Scirica","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2015.10.018_bib0070","series-title":"Heart Rhythm Society 2014 Scientific Sessions","article-title":"The effect of the combination of ranolazine and low dose dronedarone on atrial fibrillation burden in patients with paroxysmal atrial fibrillation (HARMONY trial)","author":"Kowey","year":"2014"},{"key":"10.1016\/j.phrs.2015.10.018_bib0075","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1161\/CIRCULATIONAHA.111.019893","article-title":"Atrial fibrillation pathophysiology: implications for management","volume":"124","author":"Iwasaki","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2015.10.018_bib0080","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1196\/annals.1420.012","article-title":"Atrial-selective sodium channel block as a strategy for suppression of atrial fibrillation","volume":"1123","author":"Burashnikov","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.phrs.2015.10.018_bib0085","first-page":"175","article-title":"The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation","volume":"8","author":"Murdock","year":"2008","journal-title":"Indian Pacing Electrophysiol. J."},{"key":"10.1016\/j.phrs.2015.10.018_bib0090","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.hrthm.2015.01.021","article-title":"Ranolazine in the treatment of atrial fibrillation: results of the dose-ranging RAFFAELLO (Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion) study","volume":"12","author":"De","year":"2015","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.phrs.2015.10.018_bib0095","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1540-8159.2011.03298.x","article-title":"The use of ranolazine to facilitate electrical cardioversion in cardioversion-resistant patients: a case series","volume":"35","author":"Murdock","year":"2012","journal-title":"Pacing Clin. Electrophysiol."},{"key":"10.1016\/j.phrs.2015.10.018_bib0100","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1161\/CIR.0b013e31823c074e","article-title":"ACCF\/AHA guideline for coronary artery bypass graft surgery: a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines","volume":"124","author":"Hillis","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2015.10.018_bib0105","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1111\/pace.12486","article-title":"Ranolazine as a promising treatment option for atrial fibrillation: electrophysiologic mechanisms, experimental evidence, and clinical implications","volume":"37","author":"Fragakis","year":"2014","journal-title":"Pacing Clin. Electrophysiol."},{"key":"10.1016\/j.phrs.2015.10.018_bib0110","doi-asserted-by":"crossref","first-page":"988","DOI":"10.2174\/157016111106140128123506","article-title":"Effect of ranolazine in preventing postoperative atrial fibrillation in patients undergoing coronary revascularization surgery","volume":"11","author":"Tagarakis","year":"2013","journal-title":"Curr. Vasc. Pharmacol."},{"key":"10.1016\/j.phrs.2015.10.018_bib0115","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1177\/0003319713477911","article-title":"Ranolazine enhances the antiarrhythmic activity of amiodarone by accelerating conversion of new-onset atrial fibrillation after cardiac surgery","volume":"65","author":"Simopoulos","year":"2014","journal-title":"Angiology"},{"key":"10.1016\/j.phrs.2015.10.018_bib0120","article-title":"Ranolazine for the prevention of atrial fibrillation after electrical cardioversion","author":"Bekheit","year":"2012","journal-title":"Clinicaltrials"},{"key":"10.1016\/j.phrs.2015.10.018_bib0125","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.amjcard.2011.04.017","article-title":"Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting","volume":"108","author":"Miles","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.phrs.2015.10.018_bib0130","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s00392-014-0796-x","article-title":"Short-course of ranolazine prevents postoperative atrial fibrillation following coronary artery bypass grafting and valve surgeries","volume":"104","author":"Hammond","year":"2015","journal-title":"Clin. Res. Cardiol."},{"key":"10.1016\/j.phrs.2015.10.018_bib0135","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0167-5273(96)02883-5","article-title":"Short-term low dose intracoronary diltiazem administered at the onset of reperfusion reduces myocardial infarct size","volume":"59","author":"Herzog","year":"1997","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.phrs.2015.10.018_bib0140","first-page":"H2145","article-title":"Attenuation of postischemic reperfusion injury is related to prevention of [Ca2+]m overload in rat hearts","volume":"271","author":"Miyamae","year":"1996","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.phrs.2015.10.018_bib0145","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.ahj.2012.03.018","article-title":"A pilot randomized study of ranolazine for reduction of myocardial damage during elective percutaneous coronary intervention","volume":"163","author":"Pelliccia","year":"2012","journal-title":"Am. Heart J."},{"key":"10.1016\/j.phrs.2015.10.018_bib0150","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.ahj.2013.08.004","article-title":"Use of ranolazine in patients with incomplete revascularization after percutaneous coronary intervention: design and rationale of the ranolazine for incomplete vessel revascularization post-percutaneous coronary intervention (RIVER-PCI) trial","volume":"166","author":"Weisz","year":"2013","journal-title":"Am. Heart J."},{"key":"10.1016\/j.phrs.2015.10.018_bib0155","article-title":"Ranolazine loading to prevent PCI-induced myocardial injury (TWILIGHT)","author":"Pelliccia","year":"2013","journal-title":"Clinicaltrials"},{"key":"10.1016\/j.phrs.2015.10.018_bib0160","article-title":"Effect of ranolazine on myocardial perfusion assessed by serial quantitative exercise SPECT imaging","author":"Yue","year":"2014","journal-title":"Clinicaltrials"},{"key":"10.1016\/j.phrs.2015.10.018_bib0165","article-title":"Reduction of ischemic myocardium with ranolazine-teatment in patients with acute myocardial ischemia (RIMINI)","author":"Blankenberg","year":"2015","journal-title":"Clinicaltrials"},{"key":"10.1016\/j.phrs.2015.10.018_bib0170","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1161\/CIRCULATIONAHA.112.094714","article-title":"Ranolazine decreases mechanosensitivity of the voltage-gated sodium ion channel Na(v) 1.5: a novel mechanism of drug action","volume":"125","author":"Beyder","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2015.10.018_bib0175","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/anec.12137","article-title":"Ranolazine for the suppression of ventricular arrhythmia: a case series","volume":"19","author":"Yeung","year":"2014","journal-title":"Ann. Noninvasive Electrocardiol."},{"key":"10.1016\/j.phrs.2015.10.018_bib0180","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1111\/j.1540-8159.2011.03208.x","article-title":"Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks","volume":"34","author":"Bunch","year":"2011","journal-title":"Pacing Clin. Electrophysiol."},{"key":"10.1016\/j.phrs.2015.10.018_bib0185","article-title":"Ranolazine implantable cardioverter-defibrillator trial (RAID)","author":"Zareba","year":"2015","journal-title":"Clinicaltrials"},{"key":"10.1016\/j.phrs.2015.10.018_bib0190","article-title":"Study to reduce symptoms of premature beats with ranolazine","author":"Cahill","year":"2013","journal-title":"Clinicaltrials"},{"key":"10.1016\/j.phrs.2015.10.018_bib0195","article-title":"Efficacy study of sodium channel blocker in Long QT syndrome type 3","author":"Zareba","year":"2015","journal-title":"Clinicaltrials"},{"key":"10.1016\/j.phrs.2015.10.018_bib0200","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/FJC.0b013e3181a1b9c7","article-title":"Ion channels transporters, and pumps as targets for heart failure therapy","volume":"54","author":"Doshi","year":"2009","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.phrs.2015.10.018_bib0205","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1177\/1074248410382105","article-title":"Improvement in left ventricular systolic and diastolic performance during ranolazine treatment in patients with stable angina","volume":"16","author":"Figueredo","year":"2011","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2015.10.018_bib0210","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jchf.2012.12.002","article-title":"Ranolazine for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study","volume":"1","author":"Maier","year":"2013","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.phrs.2015.10.018_bib0215","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2147\/TCRM.S82288","article-title":"Ranolazine versus placebo in patients with ischemic cardiomyopathy and persistent chest pain or dyspnea despite optimal medical and revascularization therapy: randomized, double-blind crossover pilot study","volume":"11","author":"Shammas","year":"2015","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.phrs.2015.10.018_bib0220","article-title":"The effects of ranolazine on exercise capacity in patients with heart failure with preserved ejection fraction","author":"Barnard","year":"2013","journal-title":"Clinicaltrials."},{"key":"10.1016\/j.phrs.2015.10.018_bib0225","article-title":"Treatment with ranolazine in microvascular coronary dysfunction: impact on angina myocardial ischemia (RWISE)","author":"Bairey-Merz","year":"2015","journal-title":"Clinicaltrials"},{"key":"10.1016\/j.phrs.2015.10.018_bib0230","article-title":"Microvascular assessment of ranolazine in non-obstructive atherosclerosis (MARINA)","author":"Samady","year":"2015","journal-title":"Clinicaltrials"},{"key":"10.1016\/j.phrs.2015.10.018_bib0235","article-title":"Microvascular coronary disease in women: impact of ranolazine","author":"Bairey-Merz","year":"2015","journal-title":"Clinicaltrials"},{"key":"10.1016\/j.phrs.2015.10.018_bib0240","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1124\/pr.56.2.6","article-title":"Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity","volume":"56","author":"Minotti","year":"2004","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.phrs.2015.10.018_bib0245","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1124\/jpet.113.204057","article-title":"Pharmacology at work for cardio-oncology: ranolazine to treat early cardiotoxicity induced by antitumor drugs","volume":"346","author":"Minotti","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2015.10.018_bib0250","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.phrs.2013.11.001","article-title":"Ranolazine in the prevention of anthracycline cardiotoxicity","volume":"79","author":"Corradi","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2015.10.018_bib0255","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/ejhf.50","article-title":"Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction","volume":"16","author":"Tocchetti","year":"2014","journal-title":"Eur. J. Heart Fail"},{"key":"10.1016\/j.phrs.2015.10.018_bib0260","article-title":"The ranolazine to treat early cardiotoxicity induced by antitumor drugs (INTERACT) study","author":"Minotti","year":"2013","journal-title":"Eur. Clin. Trials"},{"key":"10.1016\/j.phrs.2015.10.018_bib0265","article-title":"Ranolazine effects on ischemic mitral regurgitation severity in patients with cardiac resynchronization therapy (REIN-MR)","author":"Baljepally","year":"2013","journal-title":"Clinicaltrials"},{"key":"10.1016\/j.phrs.2015.10.018_bib0270","article-title":"Supervised treadmill exercise and ranolazine for intermittent claudication of lower extremities (STERILE)","author":"Fanny","year":"2013","journal-title":"Clinicaltrials"},{"year":"2015","author":"Han","journal-title":"Clinicaltrials","key":"10.1016\/j.phrs.2015.10.018_bib0275"},{"key":"10.1016\/j.phrs.2015.10.018_bib0280","article-title":"Phase I. study of ranolazine acute administration and short term administration in pulmonary arterial hypertension","author":"Gomberg-Maitland","year":"2015","journal-title":"Clinicaltrials"},{"key":"10.1016\/j.phrs.2015.10.018_bib0285","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/j.1540-8167.2008.01246.x","article-title":"Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome","volume":"19","author":"Moss","year":"2008","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"10.1016\/j.phrs.2015.10.018_bib0290","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ijcard.2013.11.066","article-title":"Successful treatment of a patient with symptomatic long QT syndrome type 3 using ranolazine combined with a beta-blocker","volume":"171","author":"den","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.phrs.2015.10.018_bib0295","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1161\/CIRCRESAHA.113.301971","article-title":"Ranolazine for congenital and acquired late INa-linked arrhythmias: in silico pharmacological screening","volume":"113","author":"Moreno","year":"2013","journal-title":"Circ. Res."},{"key":"10.1016\/j.phrs.2015.10.018_bib0300","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1124\/jpet.114.221861","article-title":"Ranolazine reduces remodeling of the right ventricle and provoked arrhythmias in rats with pulmonary hypertension","volume":"353","author":"Liles","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2015.10.018_bib0305","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/jce.12569","article-title":"Combined actions of ivabradine and ranolazine reduce ventricular rate during atrial fibrillation","volume":"26","author":"Verrier","year":"2015","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"10.1016\/j.phrs.2015.10.018_bib0310","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1161\/CIR.0000000000000095","volume":"130","author":"Fihn","year":"2014","journal-title":"Circulation"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661815002613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661815002613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T21:23:52Z","timestamp":1537219432000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661815002613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":62,"alternative-id":["S1043661815002613"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2015.10.018","relation":{},"ISSN":["1043-6618"],"issn-type":[{"type":"print","value":"1043-6618"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The use of ranolazine in non-anginal cardiovascular disorders: A review of current data and ongoing randomized clinical trials","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2015.10.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}